153 related articles for article (PubMed ID: 8066084)
21. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
Kreitman RJ; Batra JK; Seetharam S; Chaudhary VK; FitzGerald DJ; Pastan I
Bioconjug Chem; 1993; 4(2):112-20. PubMed ID: 7873642
[TBL] [Abstract][Full Text] [Related]
22. Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.
Reiter Y; Brinkmann U; Jung SH; Pastan I; Lee B
Protein Eng; 1995 Dec; 8(12):1323-31. PubMed ID: 8869646
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
24. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
25. Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure.
Reiter Y; Kurucz I; Brinkmann U; Jung SH; Lee B; Segal DM; Pastan I
Immunity; 1995 Mar; 2(3):281-7. PubMed ID: 7697545
[TBL] [Abstract][Full Text] [Related]
26. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.
Brinkmann U; Gallo M; Brinkmann E; Kunwar S; Pastan I
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):547-51. PubMed ID: 8421689
[TBL] [Abstract][Full Text] [Related]
27. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.
Bera TK; Onda M; Brinkmann U; Pastan I
J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563
[TBL] [Abstract][Full Text] [Related]
28. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
29. Application of 13C NMR spectroscopy to paratope mapping for larger antigen-Fab complexes.
Kim H; Kato K; Yamato S; Igarashi T; Matsunaga C; Ohtsuka H; Higuchi A; Nomura N; Noguchi H; Arata Y
FEBS Lett; 1994 Jun; 346(2-3):246-50. PubMed ID: 8013642
[TBL] [Abstract][Full Text] [Related]
30. Molecular modeling and site-directed mutagenesis of an anti-phosphotyrosine antibody predicts the combining site and allows the detection of higher affinity interactions.
Ruff-Jamison S; Glenney JR
Protein Eng; 1993 Aug; 6(6):661-8. PubMed ID: 7694275
[TBL] [Abstract][Full Text] [Related]
31. Design of a modular immunotoxin connected by polyionic adapter peptides.
Kleinschmidt M; Rudolph R; Lilie H
J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
Beers R; Chowdhury P; Bigner D; Pastan I
Clin Cancer Res; 2000 Jul; 6(7):2835-43. PubMed ID: 10914732
[TBL] [Abstract][Full Text] [Related]
33. Recombinant single-chain immunotoxins against T and B cell leukemias.
Kreitman RJ; Pastan I
Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
[TBL] [Abstract][Full Text] [Related]
34. Crystallization of single-chain Fv proteins.
Essig NZ; Wood JF; Howard AJ; Raag R; Whitlow M
J Mol Biol; 1993 Dec; 234(3):897-901. PubMed ID: 8254684
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
[TBL] [Abstract][Full Text] [Related]
36. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
Batra JK; Fitzgerald DJ; Chaudhary VK; Pastan I
Mol Cell Biol; 1991 Apr; 11(4):2200-5. PubMed ID: 2005905
[TBL] [Abstract][Full Text] [Related]
37. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
[TBL] [Abstract][Full Text] [Related]
38. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
39. Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions.
Luo D; Mah N; Krantz M; Wilde K; Wishart D; Zhang Y; Jacobs F; Martin L
J Biochem; 1995 Oct; 118(4):825-31. PubMed ID: 8576099
[TBL] [Abstract][Full Text] [Related]
40. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
